Virtual ACC 2020 | PRONOMOS: Rivaroxaban Superior to Enoxaparin in Orthopedic Surgery

According to this new study presented virtually at the suspended American College of Cardiology (ACC) 2020 Scientific Session and published simultaneously in the New England Journal of Medicine (NEJM), rivaroxaban is more effective than enoxaparin in preventing venous thromboembolism during a period of immobilization after nonmajor orthopedic surgery of a lower limb.

Pronomos: Rivaroxaban

After an orthopedic surgery, there is a transitory period of reduced mobility during which the risk of deep vein thrombosis must be prevented; so far, enoxaparin was the best option for this. The efficacy of that drug is undisputed, but its uncomfortable administration, particularly for patients on bedrest at their homes, made us continuously seek for an option that was at least noninferior.

This international double-blind, parallel-group, noninferiority study randomized patients undergoing nonmajor orthopedic surgery of a lower limb to rivaroxaban or enoxaparin.

The efficacy endpoint was a composite of symptomatic distal or proximal deep vein thrombosis, pulmonary embolism or thrombosis-related death during the treatment period, or asymptomatic deep vein thrombosis. Researchers planned to test for superiority if rivaroxaban turned out to be noninferior.


Read also: Virtual ACC 2020 | PRECOMBAT: 10 Years for Surgery vs. Angioplasty in Left Main Coronary Artery Disease.


The safety endpoint included major bleeding (fatal, critical, clinically evident bleeding, or surgical bleeding requiring a reintervention) and nonmajor clinically relevant bleeding.

The study enrolled 3604 patients; the primary endpoint rate was 0.2% for rivaroxaban vs. 1.1% for enoxaparin (p < 0.001 for noninferiority and p = 0.01 for superiority).

The rates for major bleeding were practically identical: 1.1% vs. 1%, respectively.


Read also: Virtual ACC 2020 | TWILIGHT-DM: Ticagrelor Monotherapy in Diabetic Patients.


This study represents a new landmark in the history of prevention against deep vein thrombosis, with a drug that is both much more comfortable for patients as regards the route of administration and more effective, without compromising its safety.

Original Title: Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.

Reference: C. Marc Samama et al. New England Journal of Medicine 2020, online before print y presentado simultáneamente en el ACC 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...